Burst Expert Illustrations & Commentaries™: The Impact of Targeted IL-17 Inhibition on the Treatment for Moderate to Severe Plaque Psoriasis

Target Audience This educational activity is directed toward dermatologists, nurse practitioners, and physician assistants involved in the care and treatment of patients with psoriasis. Program Overview Psoriasis is the most common immune-mediated inflammatory disease in North America and Europe, affecting approximately 8 million Americans and 125 million people worldwide. Psoriasis is a chronic, painful, disfiguring skin condition with no clearly defined cause and no cure. The critical p...
Physicians’ Education Resource®, LLC

Expert Illustrations & Commentaries Live: The Future of JAK/TYK2 Inhibition in the Treatment of Psoriasis

Target Audience This educational activity is directed toward the dermatologists, nurse practitioners, and physician assistants who treat patients with dermatologic conditions. Program Overview This online, on-demand virtual symposium brings together renowned experts in dermatology to discuss newer treatments for patients with psoriasis. Psoriasis has no clearly defined cause or cure, but it does have a significant impact on quality of life. It is now recognized as a systemic disease assoc...
Physicians’ Education Resource®, LLC

New Drugs 2019

Intended Audience: Pharmacists The number of new drugs approved each year has increased significantly since 1990. Various expedited approval pathways such as Orphan Drug Status designation, Accelerated Approval, Fast-Track, Priority Reviews, and the use of surrogate endpoints in studies have reduced the FDA review time from more than 3 years in 1983 to less than 1 year in 2017. In 2019, the FDA’s Center for Drug Evaluation and Research approved 48 novel drugs – a decline from 59 in 2018...
The Rx Consultant

Virtual Case Studies in Pustular Psoriasis: Refining Our Approaches to the Assessment of Our Patients

Target Audience These activities will be directed towards a primary target audience of dermatologists and a secondary target audience of PCPs, emergency medicine physicians, pharmacists, physician assistants, nurse practitioners, nurses, fellows, and residents. Additional healthcare clinicians involved in the management of patients with GPP and/or PPP will also be permitted to participate. Activity Overview Pustular psoriasis is a rare, severe, relapsing/remitting, multisystem disease tha...
Physicians’ Education Resource®, LLC

PosterPerspectives: Research Developments in Psoriasis

Target Audience This activity was developed for dermatologists, dermatology advanced practice providers, and other clinicians who manage patients with moderate to severe plaque psoriasis. Program Overview Plaque psoriasis is responsible for a substantial burden on patients, their families, and the healthcare system. To address this burden, important treatment advances continue to be made, including a better understanding of the long-term safety and efficacy of approved medications, as...
Annenberg Center for Health Sciences at Eisenhower.

Dermatological Compounding Home Study

This is a 5-hour knowledge-based home study learning program, designed for compounding pharmacists and technicians that will cover the definition and discussion of creams, emulsions, ointments, pastes, gels, PLOs, solutions, lotions, powders, and bases (semi-solid and commercially available). This module also covers compendial requirements (microbial content, minimum fill, quality control, preparation and labeling, patient counseling, and consultations) and establishing and extending beyon...
American College of Apothecaries

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map